News & Perspective

Oct 30, 2018

Oct 30, 2018
ebola vaccine

Ebola total hits 276 as lasting effect noted for 3 vaccines

Immune response lasted 2.5 years for the vaccines, the longest yet in ongoing studies of Ebola immunization.

Jul 05, 2016

Jul 05, 2016

News Scan for Jul 05, 2016

Ebola survivor drug study
MERS linked to camels
Reduced antibiotics
HPV and cervical abnormalities

Jul 15, 2015

Jul 15, 2015
Freetown street scene

Ebola activity steady, back in Guinea and Sierra Leone capitals

Also, phase 2 trials just launched for two prime-boost Ebola vaccine regimens.

Mar 17, 2015

Mar 17, 2015
Vials and syringe

Emergent announces human trial for boosted Ebola vaccine

Other Ebola developments include the departure of Cuba's team from Liberia, new information on evacuee contact monitoring, and outbreak case totals.

Feb 02, 2015

Feb 02, 2015
Vaccination

Ebola vaccine trial launches in Liberia

A clinical trial of 2 Ebola vaccine candidates was launched today near Liberia's capital, but falling case numbers may pose problems.

Sep 08, 2014

Sep 08, 2014
Taxi in Africa

Liberia's grim Ebola situation prompts call for 'nonconventional' help

Ebola cases are increasing exponentially in Liberia, where taxis might transmit disease.

Aug 28, 2014

Aug 28, 2014

Ebola Scan for Aug 28, 2014

Ebola vaccine gains steam
Clinical lessons from US patients

Mar 21, 2014

Mar 21, 2014

News Scan for Mar 21, 2014

MERS-CoV in man and his camel
UK panel recommends Bexsero
PAHO cholera update
New antiviral center
Grant for Ebola therapeutics

May 01, 2012

May 01, 2012

NIH preparing tool to help labs cope with new DURC policy

(CIDRAP News) – Federal officials are working on guidance to help local institutions implement the government's new policy on the oversight of life-sciences dual-use research of concern (DURC), an official from the National Institutes of Health (NIH) said today.

Sep 25, 2007

Sep 25, 2007

Wisconsin lab broke Ebola rules, watchdog group says

(CIDRAP News) – Researchers at the University of Wisconsin at Madison (UW-Madison) worked on Ebola virus genetic material in a lab that lacked the required security measures, and federal agencies responsible for monitoring compliance didn't notice the problem, a watchdog group that monitors biodefense research safety reported recently.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»